Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)

NCT04117945 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT04117945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04117945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 3, 2020
Completion date
March 31, 2025
Enrollment
22 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600e negative, kras gene mutation negative, locally advanced unresectable colorectal adenocarcinoma, metastatic colorectal adenocarcinoma, nras gene mutation negative, stage iii colorectal cancer ajcc v8, stage iiia colorectal cancer ajcc v8, stage iiib colorectal cancer ajcc v8, stage iiic colorectal cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iva colorectal cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivc colorectal cancer ajcc v8